Company registration number 07705969 (England and Wales)
M&MPHARM LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024
PAGES FOR FILING WITH REGISTRAR
M&MPHARM LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
M&MPHARM LTD
BALANCE SHEET
AS AT
31 AUGUST 2024
31 August 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
305
359
Investments
4
1,222,469
1,222,469
1,222,774
1,222,828
Current assets
Cash at bank and in hand
-
0
2,455
Creditors: amounts falling due within one year
5
(660,387)
(606,316)
Net current liabilities
(660,387)
(603,861)
Total assets less current liabilities
562,387
618,967
Creditors: amounts falling due after more than one year
6
(557,630)
(609,909)
Provisions for liabilities
(76)
(90)
Net assets
4,681
8,968
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
4,680
8,967
Total equity
4,681
8,968

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

M&MPHARM LTD
BALANCE SHEET (CONTINUED)
AS AT
31 AUGUST 2024
31 August 2024
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 13 February 2025
Mrs M Moshref
Director
Company registration number 07705969 (England and Wales)
M&MPHARM LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2024
- 3 -
1
Accounting policies
Company information

M&MPharm Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, Middlesex, HA5 5QA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

1.2
Going concern

Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
15% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

M&MPHARM LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2024
1
Accounting policies
(Continued)
- 4 -

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.6

Related party exemption

The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102,' The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
1
M&MPHARM LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2024
- 5 -
3
Tangible fixed assets
Fixtures and fittings
£
Cost
At 1 September 2023 and 31 August 2024
810
Depreciation and impairment
At 1 September 2023
451
Depreciation charged in the year
54
At 31 August 2024
505
Carrying amount
At 31 August 2024
305
At 31 August 2023
359
4
Fixed asset investments
2024
2023
£
£
Shares in group undertakings and participating interests
1,222,469
1,222,469
5
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
51,050
66,512
Amounts owed to group undertakings
498,826
426,584
Other creditors
110,511
113,220
660,387
606,316
6
Creditors: amounts falling due after more than one year
2024
2023
Notes
£
£
Bank loans and overdrafts
557,630
609,909

Bank loans are secured by way of a fixed and floating charge over the company's assets as well as its subsidiary.

M&MPHARM LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2024
6
Creditors: amounts falling due after more than one year
(Continued)
- 6 -
Amounts included above which fall due after five years are as follows:
Payable by instalments
353,429
406,165
2024-08-312023-09-01false13 February 2025CCH SoftwareCCH Accounts Production 2024.100No description of principal activityMrs M Moshreffalsefalse077059692023-09-012024-08-31077059692024-08-31077059692023-08-3107705969core:FurnitureFittings2024-08-3107705969core:FurnitureFittings2023-08-3107705969core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3107705969core:CurrentFinancialInstrumentscore:WithinOneYear2023-08-3107705969core:Non-currentFinancialInstrumentscore:AfterOneYear2024-08-3107705969core:Non-currentFinancialInstrumentscore:AfterOneYear2023-08-3107705969core:CurrentFinancialInstruments2024-08-3107705969core:CurrentFinancialInstruments2023-08-3107705969core:ShareCapital2024-08-3107705969core:ShareCapital2023-08-3107705969core:RetainedEarningsAccumulatedLosses2024-08-3107705969core:RetainedEarningsAccumulatedLosses2023-08-3107705969bus:Director12023-09-012024-08-3107705969core:FurnitureFittings2023-09-012024-08-31077059692022-09-012023-08-3107705969core:FurnitureFittings2023-08-3107705969core:Non-currentFinancialInstruments2024-08-3107705969core:Non-currentFinancialInstruments2023-08-3107705969bus:PrivateLimitedCompanyLtd2023-09-012024-08-3107705969bus:SmallCompaniesRegimeForAccounts2023-09-012024-08-3107705969bus:FRS1022023-09-012024-08-3107705969bus:AuditExemptWithAccountantsReport2023-09-012024-08-3107705969bus:FullAccounts2023-09-012024-08-31xbrli:purexbrli:sharesiso4217:GBP